A CRISPR-Cas12a—Based platform for ultrasensitive, rapid, and highly specific detection of Mycoplasma pneumonia in clinical application
Mycoplasma pneumoniae (MP), which is responsible for a majority of community-acquired pneumonia (CAP) in children, has been largely underestimated. Here, we coupled multiple cross displacement amplification (MCDA) technique with CRISPR-Cas12a-based biosensing system to design a novel detection platf...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-01-01
|
| Series: | Frontiers in Bioengineering and Biotechnology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fbioe.2023.1022066/full |
| _version_ | 1797951353191923712 |
|---|---|
| author | Nan Jia Juan Zhou Fei Xiao Baoying Zheng Xiaolan Huang Chunrong Sun Jin Fu Zheng Xu Min Chen Yi Wang |
| author_facet | Nan Jia Juan Zhou Fei Xiao Baoying Zheng Xiaolan Huang Chunrong Sun Jin Fu Zheng Xu Min Chen Yi Wang |
| author_sort | Nan Jia |
| collection | DOAJ |
| description | Mycoplasma pneumoniae (MP), which is responsible for a majority of community-acquired pneumonia (CAP) in children, has been largely underestimated. Here, we coupled multiple cross displacement amplification (MCDA) technique with CRISPR-Cas12a-based biosensing system to design a novel detection platform termed MP-MCDA-CRISPR assay for MP infection diagnosis and clinical application. The MP-MCDA-CRISPR assay amplified the CARDS gene of MP by MCDA method, followed by trans-cleavage of the reporter molecular upon the formation of CRISPR-Cas12a-gRNA-target DNA complex, which was confirmed by the release of fluorescent signals. A set of standard MCDA primers, an engineered CP1 primer, a quenched fluorescent ssDNA reporter, and a gRNA were designed targeting the CARDS gene of MP. The optimal temperature for MCDA pre-amplification is 64°C, and the time for CRISPR-Cas12a-gRNA biosensing process is 5 min. The limit of detection (LoD) of the MP-MCDA-CRISPR assay is 50 fg per reaction without any cross-reaction with other non-MP pathogens. The MP-MCDA-CRISPR assay accurately identified the 50 real time-PCR positive clinical samples and 78 negative ones. Taken together, the MP-MCDA-CRISPR assay designed here is a promising diagnostic tool for point-of care (POC) testing of MP infection. |
| first_indexed | 2024-04-10T22:29:14Z |
| format | Article |
| id | doaj.art-06070f27f287400ca1ebc5cf5be4acfc |
| institution | Directory Open Access Journal |
| issn | 2296-4185 |
| language | English |
| last_indexed | 2024-04-10T22:29:14Z |
| publishDate | 2023-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Bioengineering and Biotechnology |
| spelling | doaj.art-06070f27f287400ca1ebc5cf5be4acfc2023-01-17T06:19:20ZengFrontiers Media S.A.Frontiers in Bioengineering and Biotechnology2296-41852023-01-011110.3389/fbioe.2023.10220661022066A CRISPR-Cas12a—Based platform for ultrasensitive, rapid, and highly specific detection of Mycoplasma pneumonia in clinical applicationNan Jia0Juan Zhou1Fei Xiao2Baoying Zheng3Xiaolan Huang4Chunrong Sun5Jin Fu6Zheng Xu7Min Chen8Yi Wang9Experimental Research Center, Capital Institute of Pediatrics, Beijing, ChinaExperimental Research Center, Capital Institute of Pediatrics, Beijing, ChinaExperimental Research Center, Capital Institute of Pediatrics, Beijing, ChinaRespiratory Medicine, Capital Institute of Pediatrics, Beijing, ChinaExperimental Research Center, Capital Institute of Pediatrics, Beijing, ChinaExperimental Research Center, Capital Institute of Pediatrics, Beijing, ChinaExperimental Research Center, Capital Institute of Pediatrics, Beijing, ChinaExperimental Research Center, Capital Institute of Pediatrics, Beijing, ChinaExperimental Research Center, Capital Institute of Pediatrics, Beijing, ChinaExperimental Research Center, Capital Institute of Pediatrics, Beijing, ChinaMycoplasma pneumoniae (MP), which is responsible for a majority of community-acquired pneumonia (CAP) in children, has been largely underestimated. Here, we coupled multiple cross displacement amplification (MCDA) technique with CRISPR-Cas12a-based biosensing system to design a novel detection platform termed MP-MCDA-CRISPR assay for MP infection diagnosis and clinical application. The MP-MCDA-CRISPR assay amplified the CARDS gene of MP by MCDA method, followed by trans-cleavage of the reporter molecular upon the formation of CRISPR-Cas12a-gRNA-target DNA complex, which was confirmed by the release of fluorescent signals. A set of standard MCDA primers, an engineered CP1 primer, a quenched fluorescent ssDNA reporter, and a gRNA were designed targeting the CARDS gene of MP. The optimal temperature for MCDA pre-amplification is 64°C, and the time for CRISPR-Cas12a-gRNA biosensing process is 5 min. The limit of detection (LoD) of the MP-MCDA-CRISPR assay is 50 fg per reaction without any cross-reaction with other non-MP pathogens. The MP-MCDA-CRISPR assay accurately identified the 50 real time-PCR positive clinical samples and 78 negative ones. Taken together, the MP-MCDA-CRISPR assay designed here is a promising diagnostic tool for point-of care (POC) testing of MP infection.https://www.frontiersin.org/articles/10.3389/fbioe.2023.1022066/fullMycoplasma pneumoniaemultiple cross displacement amplificationCRISPRCas12acommunity-acquired pneumonia |
| spellingShingle | Nan Jia Juan Zhou Fei Xiao Baoying Zheng Xiaolan Huang Chunrong Sun Jin Fu Zheng Xu Min Chen Yi Wang A CRISPR-Cas12a—Based platform for ultrasensitive, rapid, and highly specific detection of Mycoplasma pneumonia in clinical application Frontiers in Bioengineering and Biotechnology Mycoplasma pneumoniae multiple cross displacement amplification CRISPR Cas12a community-acquired pneumonia |
| title | A CRISPR-Cas12a—Based platform for ultrasensitive, rapid, and highly specific detection of Mycoplasma pneumonia in clinical application |
| title_full | A CRISPR-Cas12a—Based platform for ultrasensitive, rapid, and highly specific detection of Mycoplasma pneumonia in clinical application |
| title_fullStr | A CRISPR-Cas12a—Based platform for ultrasensitive, rapid, and highly specific detection of Mycoplasma pneumonia in clinical application |
| title_full_unstemmed | A CRISPR-Cas12a—Based platform for ultrasensitive, rapid, and highly specific detection of Mycoplasma pneumonia in clinical application |
| title_short | A CRISPR-Cas12a—Based platform for ultrasensitive, rapid, and highly specific detection of Mycoplasma pneumonia in clinical application |
| title_sort | crispr cas12a based platform for ultrasensitive rapid and highly specific detection of mycoplasma pneumonia in clinical application |
| topic | Mycoplasma pneumoniae multiple cross displacement amplification CRISPR Cas12a community-acquired pneumonia |
| url | https://www.frontiersin.org/articles/10.3389/fbioe.2023.1022066/full |
| work_keys_str_mv | AT nanjia acrisprcas12abasedplatformforultrasensitiverapidandhighlyspecificdetectionofmycoplasmapneumoniainclinicalapplication AT juanzhou acrisprcas12abasedplatformforultrasensitiverapidandhighlyspecificdetectionofmycoplasmapneumoniainclinicalapplication AT feixiao acrisprcas12abasedplatformforultrasensitiverapidandhighlyspecificdetectionofmycoplasmapneumoniainclinicalapplication AT baoyingzheng acrisprcas12abasedplatformforultrasensitiverapidandhighlyspecificdetectionofmycoplasmapneumoniainclinicalapplication AT xiaolanhuang acrisprcas12abasedplatformforultrasensitiverapidandhighlyspecificdetectionofmycoplasmapneumoniainclinicalapplication AT chunrongsun acrisprcas12abasedplatformforultrasensitiverapidandhighlyspecificdetectionofmycoplasmapneumoniainclinicalapplication AT jinfu acrisprcas12abasedplatformforultrasensitiverapidandhighlyspecificdetectionofmycoplasmapneumoniainclinicalapplication AT zhengxu acrisprcas12abasedplatformforultrasensitiverapidandhighlyspecificdetectionofmycoplasmapneumoniainclinicalapplication AT minchen acrisprcas12abasedplatformforultrasensitiverapidandhighlyspecificdetectionofmycoplasmapneumoniainclinicalapplication AT yiwang acrisprcas12abasedplatformforultrasensitiverapidandhighlyspecificdetectionofmycoplasmapneumoniainclinicalapplication AT nanjia crisprcas12abasedplatformforultrasensitiverapidandhighlyspecificdetectionofmycoplasmapneumoniainclinicalapplication AT juanzhou crisprcas12abasedplatformforultrasensitiverapidandhighlyspecificdetectionofmycoplasmapneumoniainclinicalapplication AT feixiao crisprcas12abasedplatformforultrasensitiverapidandhighlyspecificdetectionofmycoplasmapneumoniainclinicalapplication AT baoyingzheng crisprcas12abasedplatformforultrasensitiverapidandhighlyspecificdetectionofmycoplasmapneumoniainclinicalapplication AT xiaolanhuang crisprcas12abasedplatformforultrasensitiverapidandhighlyspecificdetectionofmycoplasmapneumoniainclinicalapplication AT chunrongsun crisprcas12abasedplatformforultrasensitiverapidandhighlyspecificdetectionofmycoplasmapneumoniainclinicalapplication AT jinfu crisprcas12abasedplatformforultrasensitiverapidandhighlyspecificdetectionofmycoplasmapneumoniainclinicalapplication AT zhengxu crisprcas12abasedplatformforultrasensitiverapidandhighlyspecificdetectionofmycoplasmapneumoniainclinicalapplication AT minchen crisprcas12abasedplatformforultrasensitiverapidandhighlyspecificdetectionofmycoplasmapneumoniainclinicalapplication AT yiwang crisprcas12abasedplatformforultrasensitiverapidandhighlyspecificdetectionofmycoplasmapneumoniainclinicalapplication |